Synergic effects of the cyclin-dependent kinase (CDK) inhibitor olomoucine and androgen-antagonist bicalutamide on prostatic cancer cell lines. [electronic resource]

By: Contributor(s): Producer: 20050217Description: 358-67 p. digitalISSN:
  • 0028-2685
Subject(s): In: Neoplasma vol. 51
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
No physical items for this record

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

There are no comments on this title.

to post a comment.